(Q33387704)

26 July 2017

title

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer (English)

1 reference

26 July 2017

1 reference

Sean P Dineen

1

0 references

Adam W. Beck

object named as

Adam W Beck

3

0 references

author name string

Laura A Sullivan

2

1 reference

26 July 2017

Andrew F Miller

4

1 reference

26 July 2017

Juliet G Carbon

5

1 reference

26 July 2017

Roni Mamluk

6

1 reference

26 July 2017

Henry Wong

7

1 reference

26 July 2017

Rolf A Brekken

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

27 November 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

page(s)

352

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-8-352

26 July 2017

exact match

0 references

cites work

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

21 June 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Angiogenesis: an organizing principle for drug discovery?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Vascular endothelial growth factor (VEGF) signaling in tumor progression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Biopharmaceutical drug discovery using novel protein scaffolds

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Molecular and functional diversity of vascular endothelial growth factors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

21 June 2018

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Vascular endothelial growth factor as a marker of tumor endothelium.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2627916

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-352

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-352

Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19038046

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-8-352

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference